funding_articleConfidence: medium
Uncommon Therapeutics | Y Combinator
Disease-focused biotech building multiple programs; seed backed by YC.
Affected score: noObserved: May 20, 2026
U
Uncommon Therapeutics
SeedFunding signalMarket data is refreshed once per day from public sources. Information may be incomplete or outdated — verify independently before making decisions. This is not investment advice.
Investor read
Evidence-bound summary — expand sections for movement, risks, and signals.
Memo snapshot · May 20, 2026, 6:24 PM
Insufficient evidenceEvidence-bound analyst verdict
- •Funding: Raised $500K across 1 funding round. Latest: $500K Seed (Feb 2025). Investors: Y Combinator, Angel Operator Partners.
- •Named backers in indexed sources: Y Combinator, Angel Operator Partners.
What would change this read
- →Open roles appearing would signal burn capacity and growth intent.
- →Product launches or public engineering activity would evidence execution.
DealFlow OS uses public web data and automated enrichment. Research may be incomplete, outdated, or incorrect. Verify important information before making investment or outreach decisions.
TL;DR
Seed (YC)uncommon therapeutics Official site describing unCommon Era therapeutic approach.
Funding
Raised $500K across 1 funding round. Latest: $500K Seed (Feb 2025). Investors: Y Combinator, Angel Operator Partners. (High).
Quick read
- •uncommon therapeutics Official site describing unCommon Era therapeutic approach.
- •Sector narrative limited in indexed snippets; verify on primary sources (uncommontherapeutics.com).
Key signals
Funding
Raised $500K across 1 funding round. Latest: $500K Seed (Feb 2025). Investors: Y Combinator, Angel Operator Partners. (High).
Product / news
Limited product/news coverage in corpus (Low).
Evidence summary
Verified facts
- •uncommon therapeutics Official site describing unCommon Era therapeutic approach.
- •Sector narrative limited in indexed snippets; verify on primary sources (uncommontherapeutics.com).
Recent movers
- •May 20, 2026 · ycombinator.com — Uncommon Therapeutics | Y Combinator
- •May 20, 2026 · ycombinator.com — Uncommon Therapeutics | Y Combinator
- •Y Combinator
- •Angel Operator Partners
Suggested next steps
- ▸Run a manual rescrape or add sources before forming a view — the current corpus is too thin.
Funding & hiring signals
Open roles (indexed)
No open roles indexed yet.
Public index
66Activity 64/100Moderate public activity signal
7D-13 (-16.5%)
30D+11 (+20.0%)
Needs Review
The index price and activity score are algorithmic estimates based on observed public company-level signals. They may be incomplete, stale, or inaccurate and are not investment, legal, tax, or business advice.
Source health
- public_page:homeokLast checked Thu, Jul 2, 03:33 PM
- public_market_enrichmentokLast checked Mon, May 11, 05:01 AM
- public_page:_okLast checked Mon, May 11, 05:01 AM
Public source summary
- Total evidence rows
- 3
- Latest evidence
- Thu, Jul 2, 03:33 PM
Source types found
funding_articleofficial_site
Strongest / recent news-style rows
- Uncommon Therapeutics | Y Combinator
Wed, May 20, 06:24 PM · confidence 88%high quality
Public signal timeline
Newest first · 3 event(s)
1
Thu, Jul 2, 03:33 PM · official_site · 90% · publichigh qualityuncommon therapeutics
Source ↗Source: Homepage
uncommon therapeutics 0 Skip to Content uncommon therapeutics Open Menu Close Menu uncommon therapeutics Open Menu Close Menu Welcome to the unCommon Era (0 uCE).Using the latest technologies to efficiently build drugs that target the underlying cause of rare…
2
Mon, Jun 29, 04:46 AM · official_site · 75% · publichigh qualityuncommon therapeutics
Source ↗Source: official_site
uncommon therapeutics 0 Skip to Content uncommon therapeutics Open Menu Close Menu uncommon therapeutics Open Menu Close Menu Welcome to the un Common Era (0 u CE). Using the latest technologies to efficiently build drugs that target the underlying cause of r…
3
Wed, May 20, 06:24 PM · funding_article · 88% · verified_publichigh qualityUncommon Therapeutics | Y Combinator
Source ↗Disease-focused biotech building multiple programs; seed backed by YC.
Official / company site
2 row(s)
The company's own site — the authoritative description of what they sell and to whom. Marketing-controlled, so treat claims as positioning rather than verified traction.
official_site·Thu, Jul 2, 03:33 PM·Confidence 90%high qualitypublic
uncommon therapeuticsuncommon therapeutics 0 Skip to Content uncommon therapeutics Open Menu Close Menu uncommon therapeutics Open Menu Close Menu Welcome to the unCommon Era (0 uCE).Using the latest technologies to efficiently build drugs that target the underlying cause of rare…
Why it matters: Primary source — the company's own positioning; best read for what they sell and to whom, not for traction claims.
Open source ↗official_site·Mon, Jun 29, 04:46 AM·Confidence 75%high qualitypublic
uncommon therapeuticsuncommon therapeutics 0 Skip to Content uncommon therapeutics Open Menu Close Menu uncommon therapeutics Open Menu Close Menu Welcome to the un Common Era (0 u CE). Using the latest technologies to efficiently build drugs that target the underlying cause of r…
Why it matters: Primary source — the company's own positioning; best read for what they sell and to whom, not for traction claims.
Open source ↗Funding / news
1 row(s)
Funding announcements and investor-database records. The strongest public signal of capitalization: round, amount, and syndicate quality when disclosed.
funding_article·Wed, May 20, 06:24 PM·Confidence 88%high qualityverified_public
Uncommon Therapeutics | Y CombinatorDisease-focused biotech building multiple programs; seed backed by YC.
Why it matters: Funding signal — Seed per this source; verify against the linked original before relying on it.
Open source ↗Private workspace
Sign in as an active team member to view private notes, watchlist controls, transcript evidence, and interaction history.